Skip to content

Efficacy and Safety of Silicone Gel Containing Vitamin C Ester in Improving Post-Cesarean Section Scars: A Multicenter, Prospective, Real-World Study

Efficacy and Safety of Silicone Gel Containing Vitamin C Ester in Improving Post-Cesarean Section Scars: A Multicenter, Prospective, Real-World Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126388
Enrollment
Unknown
Registered
2026-06-08
Start date
2026-06-10
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-cesarean section scar

Interventions

Control group (no silicone gel with vitamin C ester):None
Observation group (silicone gel with vitamin C ester):None

Sponsors

The Third Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 49 Years

Inclusion criteria

Inclusion criteria: 1. Undergoing primary cesarean section with complete healing of the abdominal surgical incision postoperatively. 2. Female patients aged 18 to 49 years. 3. Willing to comply with follow-up. 4. Having signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Participants currently involved in other interventional clinical trials. 2. Females taking or likely to take medications that may affect outcome assessment, including but not limited to systemic corticosteroids, immunosuppressive agents, or long-term anti-inflammatory drugs. 3. Complicated with diabetes (including type 1 diabetes, type 2 diabetes, gestational diabetes, and other specific types of diabetes), or other diseases affecting incision healing, such as gestational hypertension, body mass index (BMI) > 30 kg/m², etc. 4. Received other anti-scar therapies within one month prior to enrollment, active abdominal infection, abdominal or pelvic tumor, severe or uncontrolled diseases (such as cardiovascular, renal, hepatic, pulmonary or gastrointestinal diseases, malignant tumor, or HIV infection), or previous treatment involving the lower abdominal wall. 5. Known hypersensitivity to silicone preparations or vitamin C derivatives. 6. Other conditions judged by the investigator as inappropriate for enrollment.

Design outcomes

Primary

MeasureTime frame
Between-group differences in the magnitude of improvement in Vancouver Scar Scale (VSS) scores;

Secondary

MeasureTime frame
Between-group differences in patient satisfaction with scar improvement.;In the observation group, patient satisfaction with scar improvement.;Between-group differences in the magnitude of improvement in Vancouver Scar Scale (VSS) scores and Visual Analogue Scale (VAS) scores for pain and pruritus, as well as scar photographs.;In the observation group, the magnitude of improvement in Vancouver Scar Scale (VSS) scores and Visual Analogue Scale (VAS) scores for pain and pruritus compared with baseline, as well as scar photogr;In the observation group, the magnitude of improvement in Visual Analogue Scale (VAS) scores for pain and pruritus compared with baseline.;In the observation group, the magnitude of improvement in Vancouver Scar Scale (VSS) scores compared with baseline, as well as scar photographs.;AE;Between-group differences in the magnitude of improvement in Visual Analogue Scale (VAS) scores for pain and pruritus.;

Countries

China

Contacts

Public ContactChen Dunjin

The Third Affiliated Hospital of Guangzhou Medical University

gzdrchen@gzhmu.edu.cn+86 18928916722

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026